Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avalo Therapeutics (AVTX) Long-Term Debt Repayments (2016 - 2023)

Avalo Therapeutics (AVTX) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $6.0 million as the latest value for Q2 2023.

  • For the quarter ending Q2 2023, Long-Term Debt Repayments fell 60.0% year-over-year to $6.0 million, compared with a TTM value of $6.0 million through Dec 2024, down 3.13%, and an annual FY2023 reading of $21.2 million, changed N/A over the prior year.
  • Long-Term Debt Repayments was $6.0 million for Q2 2023 at Avalo Therapeutics, up from -$14.8 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $15.0 million in Q2 2022 and bottomed at -$14.8 million in Q4 2022.
  • Average Long-Term Debt Repayments over 3 years is $921448.6, with a median of $24342.0 recorded in 2019.
  • Peak annual rise in Long-Term Debt Repayments hit 60.0% in 2023, while the deepest fall reached 60.0% in 2023.
  • Year by year, Long-Term Debt Repayments stood at $183114.0 in 2019, then crashed by 8185.67% to -$14.8 million in 2022, then soared by 140.52% to $6.0 million in 2023.
  • Business Quant data shows Long-Term Debt Repayments for AVTX at $6.0 million in Q2 2023, -$14.8 million in Q4 2022, and $15.0 million in Q2 2022.